Introduction
Cellular mechanisms of drug resistance fall generally into two classes: those that prevent drugs from reaching their target and those that cause genetic changes that affect drug sensitivity [1] . ATP-binding cassette (ABC) transport proteins are known to induce resistance due to their ability to lower intracellular drug concentrations in an energy-dependent manner [1] . P-glycoprotein (Pgp), the product of the MDR1 (ABCB1) gene, has been studied extensively and is known to transport a wide range of chemotherapy drugs such as the anthracyclines, vinca alkaloids, taxanes, etoposide,
a r t i c l e i n f o
Article history: mitoxantrone, bisantrene and the histone deacetylase inhibitor depsipeptide [1] [2] [3] . Subsequent to the discovery of Pgp, the multidrug resistance-associated protein, MRP1 (ABCC1), was cloned from lung carcinoma cells selected in doxorubicin [4] and was found to confer resistance to etoposide, vincristine and doxorubicin [5] . The most recently reported ABC transporter associated with drug resistance, ABCG2, is a halftransporter whose substrates include mitoxantrone, topotecan, and flavopiridol [6] . Determining the contribution of Pgp to clinical drug resistance in cancer has not been an easy task, in no small part due to the lack of uniformity in methods used to measure Pgp expression [7] . However, several studies have described increased Pgp expression after initial chemotherapy treatment, especially in leukemia and breast cancer [8] . Pgp expression has also repeatedly been linked to poor outcome in some forms of leukemia [8, 9] . Targeting Pgp has led to the development of Pgp inhibitors that are able to block transport of substrates and increase intracellular accumulation. Many inhibitors have been tested in clinical trials, but definitive proof that inhibition of drug efflux can improve clinical outcome has not been forthcoming. The ''first generation'' Pgp inhibitors, generally compounds already used to treat other conditions, lacked sufficient potency and early clinical trials were largely unsuccessful [10] . ''Second generation'' Pgp inhibitors such as valspodar (PSC833) were potent but had deleterious pharmacokinetic interactions leading to some patients receiving inadequate levels of chemotherapy [10] . Some ''third generation'' compounds, such as elacridar and tariquidar, have been developed and are currently being explored in the clinic [11, 12] ; however, the merits of this treatment strategy have been debated and relatively few trials are ongoing.
Large-scale studies linking MRP1 expression to drug resistance in cancer are lacking. MRP1 expression has been found in lung carcinoma samples with incidences of 80% in SCLC to 100% in NSCLC [8, 13, 14] . CNS cancers have also been reported to express MRP1 [15] . MRP1 has been detected in leukemia samples by functional assays [16, 17] , and coexpression of MRP1 with Pgp has been found to be a negative prognostic factor in AML [17] . ABCG2, still in its relative infancy as a transporter, has not yet been conclusively linked to clinical drug resistance, although at least one large-scale study linked expression to poor outcome in acute myelogenous leukemia [18] .
Recently, a cDNA array analysis of 170 pretreatment acute myeloid leukemia samples classified the samples in six separate groups based on unsupervised clustering of the gene expression profiles using the HG_U95Av2 microarray [19] . These groups differed in clinical outcome; impressively, one of the groups with the highest poorest outcome exhibited ABC transporter overexpression [19] . Thus, despite the difficulties experienced to date in the clinical development of ABC transporter inhibitors, results such as these suggest that there is ample reason to continue this effort.
CBT 
Cell lines
SW620 parental and Pgp-overexpressing, doxorubicinselected SW620 Ad5, Ad20 and Ad300 cells have been previously described and are maintained in RPMI-1640 medium, with the drug selected sublines additionally maintained in 5, 20, or 300 ng/ml adriamycin [22] . Empty-vector transfected human embryonic kidney (HEK293) pcDNA3-10 cells, ABCB1-transfected MDR-19 cells and ABCG2-transfected R-5 cells are maintained in Eagle's medium with 2 mg/ml G418 as previously described [23] . ABCC1-transfected cells are maintained in 5 mM etoposide [24] .
Flow cytometry
Cells were trypsinized and incubated for 30 min in complete medium (phenol red-free Richter's medium with 10% FCS and penicillin/streptomycin) with the desired fluorescent substrate (0.5 mg/ml rhodamine 123, 1 mM pheophorbide a (PhA) or 0.2 mM calcein AM) in the presence or absence of the desired inhibitor for 30 min at 37 8C in 5% CO 2 . Subsequently, cells were washed and incubated in substrate-free medium for 1 h at 37 8C continuing with or without inhibitor. Transport of mitoxantrone (3 mM) was examined in a similar manner [25] .
To determine the duration of inhibition by the various Pgp Serum samples from the phase II study as well as serum from a normal volunteer were diluted 1:1 with complete medium containing 1 mg/ml rhodamine 123, resulting in a final rhodamine concentration of 0.5 mg/ml, and were added to mononuclear cells from a normal volunteer and were incubated at 37 8C for 30 min. Serum from a normal volunteer was run in parallel and diluted 1:1 with medium containing 1 mg/ml rhodamine with 6 mg/ml valspodar, 20, 2 or 0.2 mM CBT-1 1 that was then added to mononuclear cells to serve as positive controls. This resulted in a final concentration of 0.5 mg/ml rhodamine with 3 mg/ml valspodar, 10, 1, or 0.1 mM CBT-1 1 . Cells were then washed and allowed to incubate for 1 h continuing with control serum or patient serum diluted 1:1 with rhodamine-free medium. Cells incubated with rhodamine and valspodar or CBT-1 1 were washed and incubated with control serum diluted 1:1 with rhodamine-free medium containing the inhibitors. After 1 h at 37 8C, the cells were incubated with phycoerythrin-labeled anti-CD56 antibody (BD Bioscience) as previously described, and intracellular rhodamine fluorescence in CD56+ cells was measured [26] . Rhodamine and calcein fluorescence was measured on a FACSort flow cytometer equipped with a 488 nm argon laser and 530 nm bandpass filter; phycoerythrin fluorescence was measured with a 570 nm bandpass filter. Pheophorbide a or mitoxantrone fluorescence was measured with a 635 nm red diode laser and a 561 nm longpass filter. At least 10,000 events were collected for all samples and debris was eliminated by gating on forward versus side scatter; dead cells were excluded based on propidium iodide staining.
Cytotoxicity assays
Four-day cytotoxicity assays were performed based on the method of Skehan et al. [27] . Briefly, cells were plated (5000-10,000 cells/well) in 96-well, flat-bottom plates and allowed to attach overnight at 37 8C in 5% CO 2 . Chemotherapeutic agents were subsequently added to the cells at various concentrations and allowed to incubate for 96 h. Cells were then fixed with 50% (w/v) trichloroacetic acid and then stained with 0.4% sulforhodamine B (w/v) in 1% acetic acid. After washing the plates in 1% acetic acid and allowing them to dry, the dye was then solubilized in 50% Trizma base and plates were read at an absorbance of 540 nm. Each drug concentration was tested in quadruplicate and controls were tested in replicates of eight. 
Photolabeling of Pgp with [ 125 I]-IAAP
As previously described, crude membranes from HiFive insect cells expressing Pgp were incubated with 10 mM of the desired inhibitor for 10 min after which 3-6 nM [
125 I]-IAAP (2200 Ci/ mole) in 50 mM Tris-HCl (pH 7.5) was added and the samples were incubated for an additional 5 min in the dark [28] . Samples were then exposed to a UV light source for 10 min at room temperature. Pgp was then immunoprecipitated with the C219 antibody (Signet Laboratories, Dedham, MA). Protein a sepharose beads (100 ml, Amersham Biosciences, Piscataway, NJ) were then added and incubated for 16 h at 4 8C. The beads were centrifuged at 13,000 rpm for 5 min at 4 8C and then washed with RIPA buffer in 1% aprotinin. SDS-PAGE sample buffer (25 ml) was then added and the samples were incubated for 1 h at 37 8C, followed by the addition of 25 ml of water and an additional incubation at 37 8C for 30 min. Samples were separated by PAGE on a 7% Tris-acetate gel, followed by drying, exposure to Bio-Max MR film (EastmanKodak, Rochester, NY) and quantitation of the resulting bands. The data were fitted using the program GraphPad Prism 4.0 (GraphPad Software, San Diego, CA).
Determination of ATPase activity
The ATPase activity of Pgp was measured as previously described [29] . Briefly, crude membranes isolated from Pgpexpressing HiFive insect cells (100 mg protein/ml) were incubated with varying concentrations of CBT-1 1 in the presence or absence of 0.2 mM beryllium sulfate and 2.5 mM sodium fluoride (BeFx) in ATPase assay buffer (50 mM Tris-HCl pH 6.8, 100 mM KCl, 10 mM sodium azide, 20 mM EGTA, 20 mM DTT, 20 mM MgCl 2 ) for 5 min at 37 8C. The reaction was started by the addition of 5 mM ATP and was stopped by the addition of 0.1 ml of 5% SDS solution. The amount of inorganic phosphate released and the BeFx-sensitive ATPase activity of Pgp was determined [29] .
Results

CBT-1 W inhibits Pgp-mediated efflux of rhodamine 123
The ability of CBT- inhibit rhodamine 123 efflux at a concentration of 0.1 mM (heavy solid line) in the Ad20, Ad300, and MDR-19 cell lines, while complete inhibition was observed at 1 mM (solid line). When cells were incubated with 1 mM CBT in the presence of rhodamine, an increase in fluorescence was consistently observed compared to cells incubated with 10 mM CBT-1 1 in the presence of rhodamine. This was only statistically significant for the Ad20 subline ( p < 0.01). Valspodar, shown in the second column, was comparably potent. Tariquidar completely inhibited rhodamine transport at 0.1 mM (heavy solid line) in the Ad20, Ad300, and MDR-19 cell lines, making it the most potent inhibitor examined. Verapamil, shown in the last column, was a relatively poor inhibitor, since 10 mM (dashed line) was required to completely prevent rhodamine transport in all of the Pgp-overexpressing cell lines. Intracellular rhodamine fluorescence values are compiled in Supplemental Table 1 . Table 2 . Unlike with rhodamine, 10 mM CBT-1 1 did not decrease intracellular fluorescence of mitoxantrone (Supplemental Fig. 1A) or BODIPY-prazosin (data not shown) compared to 1 mM.
Duration of Pgp inhibition
We next sought to determine how long the effects of Pgp inhibition would last once the inhibitor had been removed, and compared CBT-1 1 to the other known inhibitors in this context. In Ad20 ( Fig. 2A and B) and Ad300 ( Fig. 2C and D) cells, in the absence of any inhibitor (empty squares), intracellular rhodamine fluorescence is low at the 0 time point, rapidly decreases over time and is nearly gone after 30 min. Of the inhibitors examined, the effects of verapamil were most rapidly reversed (filled circles). The duration of inhibition by 10 mM CBT-1 1 (empty circles) and valspodar (empty diamonds) was comparable in the Ad20 cell line (Fig. 2B) as both compounds effectively prevented rhodamine efflux over the entire 120 min period after the inhibitor was washed out. At 1 mM, however, in the Ad20 cell line ( Fig. 2A) , the effects of valspodar (empty diamonds) begin to deteriorate after 30 min, whereas the effects of CBT-1 1 (empty circles) just begin to wear off after 120 min. At the 30, 60 and 120 min time points, rhodamine fluorescence in cells incubated with CBT-1 1 was significantly higher than in Ad20 cells incubated with valspodar ( p < 0.02 in all cases). In the Ad300 cell line (Fig. 2C and D) , the effects of 1 or 10 mM valspodar (empty diamonds) were again significantly more rapidly lost than with a similar concentration of CBT-1 1 (empty circles) after the 30, 60 and 120 min incubation ( p < 0.03 in all cases). For both the Ad20 and Ad300 sublines, tariquidar (filled triangles), even at a concentration of 1 mM was able to maintain intracellular rhodamine fluorescence for nearly the entire 2 h after the inhibitor was washed out of the cells, a result in agreement with previous reports [30] . of results is given in Table 1 . 1 was 0.14 mM (Fig. 4B ). This compares favorably to previously published values for other known Pgp inhibitors such as biricodar (VX-710), 0.75 mM; cyclosporine a, 3.5 mM; and verapamil, >100 mM [31] .
The effects of CBT-1 1 on ATP hydrolysis were then determined as described in Section 2. Fig. 4C shows that CBT-1 1 initially stimulates Pgp-hydrolysis at low concentrations (<1 mM), then loses this stimulatory effect with increasing concentrations of CBT-1
1
. This has also been reported for other Pgp inhibitors such as MS-209 [31] . The concentration of CBT-1 1 required for 50% stimulation of the maximum ATP hydrolysis value was found to be 0.28 mM (Fig. 4D ).
CBT-1 W inhibits MRP1-mediated transport
To determine whether CBT-1 1 interacts with MRP1, calcein transport was examined in ABCC1-transfected HEK293 cells in the presence of varying concentrations of CBT-1 Table 3 . Similar results were obtained when mitoxantrone was used as a substrate (Supplemental Fig. 1B) , and results are compiled in Supplemental Table  2 . Since CBT-1 1 was found to be toxic at 10 mM, combination studies could not be performed. Our results show that CBT-1 1 is able to prevent transport mediated by either Pgp or MRP1. Inhibition of MRP1, however, occurs at a higher concentration than Pgp, suggesting CBT-1 1 has a greater affinity for Pgp than MRP1.
3.6. CBT-1 W does not modulate ABCG2-mediated pheophorbide a or mitoxantrone transport
We have previously reported that some Pgp inhibitors, such as tariquidar and elacridar, can additionally inhibit ABCG2- 
Discussion
In the present study, we characterized the interactions of the Pgp inhibitor CBT-1 1 with Pgp, MRP1 and ABCG2-ABC transporters associated with drug resistance. We found that 1 mM CBT- addition to acting as a Pgp inhibitor, 10 mM CBT- or paclitaxel. When the ''second generation'' Pgp inhibitor valspodar was used in combination with chemotherapy, it was necessary to reduce the dose of the chemotherapy drug to prevent toxicity [34] . The need for dose reduction was later found to be due to interactions with the cytochrome P450 pathway by valspodar, thus inhibiting drug metabolism and decreasing drug clearance [8] . Biricodar has also been shown reduce clearance of paclitaxel, suggesting a potential pharmacokinetic interaction as well [35] . We have argued this pharmacokinetic interaction represented an insurmountable problem for valspodar. Such a considerable variability in the pharmacokinetic interaction was observed that, despite reduction of the anticancer drug dose, about one-third of patients still had toxicity related to the anticancer drug [10] .
Furthermore, approximately one-third of patients experienced little drug toxicity and were effectively undertreated [10] . A Pgp inhibitor without major drug interactions would be valuable. CBT-1 1 may thus be an improvement over current inhibitors of ABC transporters. To date, no MRP1-specific inhibitors have been evaluated in the clinic. The only other inhibitors shown to inhibit Pgp and MRP1 and subsequently used in clinical trials are dofequidar (MS-209) [36] [37] [38] and biricodar (VX-710) [39, 40] . Dofequidar in combination with cyclophosphamide, doxorubicin and fluorouracil (CAF) was found to increase overall response rate compared to CAF alone [36] . Early in vitro studies showed biricodar to be a potent inhibitor of both Pgp and MRP1 [31, 41] , while subsequent studies also demonstrated it to be an inhibitor of ABCG2 [25] . While the value of inhibitors that are capable of inhibiting multiple transporters has yet to be determined clinically, some groups have reported expression of multiple transporters in clinical samples, particularly in leukemia [19, 42] . Daunorubicin and mitoxantrone, both substrates of Pgp and MRP1, are often used in chemotherapy regimens used to treat leukemia [18] . Inclusion of CBT- 
necessary to inhibit MRP1 in transfected cells where levels are relatively high, we will need to evaluate whether levels of CBT-1 1 achieved in patients would be able to inhibit physiologic levels of MRP1 that would tend to be lower than those observed in transfected cells. Few Pgp inhibitors remain in development. To our knowledge, only elacridar, tariquidar and dofequidar are in trials in addition to CBT-1 1 . The in vitro studies presented here demonstrate that tariquidar is more potent than CBT-1 1 . However, it is not certain that the ideal modulator will be the most potent available. Indeed, the only patients with renal cell carcinoma remaining free of disease following treatment with valspodar and vinblastine on our phase I trial received the oral formulation; no other responses were observed with the more potent IV agent [43] . It may be that an agent with somewhat lesser potency will have fewer drug interactions; or that there will be less effect on bone marrow stem cells. Given the importance of ABC transporters in protecting bone marrow stem cells, a very potent Pgp inhibitor may require reduction of the anticancer agent dose to prevent prolonged neutropenia. If CBT-1 1 can avoid both of these pitfalls and distribute well into tumors, it may become the simplest strategy for improving the efficacy of Pgp substrate drugs.
As cancer therapy has become increasingly outpatientbased, there has been a drive to develop oral agents. Thus, an oral Pgp inhibitor could be combined with an oral anticancer agent for a more prolonged schedule of administration. We know from the phase I and II trials already conducted that 7 days of CBT-1 1 is well tolerated. This could serve as the basis of a trial combining CBT-1 1 with substrates such as etoposide or imatinib, both orally administered agents. Obviously, the tolerability of continuous dosing for CBT-1 1 would have to be demonstrated for such a strategy to succeed. CBT-1 1 has been in clinical trials for over a decade, in small studies that have consistently confirmed its safety. The past few years have seen numerous trials with other modulators open and close, in many cases due to toxicity; in others, increasingly due to poor trial design; and still others with a clearly negative result. If CBT-1 1 were to succeed as a Pgp inhibitor, it would be proof that effective treatments need not come from large pharmaceutical companies.
